Phase 1 N=119 BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
B-cell Lymphoid Malignancies
Primary: Part 1 : Number Of Participants Experiencing Adverse Events — 12; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=18 Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia
Primary: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC) From Time 0 to 48 Hours After Dosing (AUC[0-48]) of Oral Omadacycline on Day 2 — 9.93 Hours x…
Phase 1 N=42 Hypertrophic Regression With N-Acetylcysteine in HCM
Hypertrophic Cardiomyopathy
Primary: Recruitment as Assessed by Number of Participants Who Enrolled to the Study — 29; 13 Participants
Phase 1 N=5 Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. — 1 Participants
Phase 1 N=190 Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Cytomegalovirus Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 75.0; 92.9; 84.6; 100.0 Percentage of participants
Phase 1 N=12 Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL) — 14.4; 6.54 hr*μM
Phase 1 N=42 Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
Bronchopulmonary Dysplasia · Bronchopulmonary Dysplasia Associated Pulmonary Hypertension · Pulmonary Hypertension
Primary: Change in Plasma Levels of L-arginine and L-citrulline as Measured by LCMS Approach — 24; 33; 26; 112 micromol/L
Phase 1 N=44 A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
B-cell Lymphoma
Primary: Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events — 11; 10; 2; 2 Participants
Phase 1 N=43 H3N2 M2SR in Pediatric Population
Influenza · Influenza Immunisation
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 0; 0 Participants
Phase 1 N=98 Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults
Healthy Volunteer
Primary: Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 2; 0; 0; 1 Participants
Phase 1 N=23 Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
Bioavailability
Primary: Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose — 821; 2100…
Phase 1 N=56 Single Ascending Dose Study of AMG 570 in Healthy Subjects
Systemic Lupus Erythematosus
Primary: Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs) — 6; 5; 4; 4 Participants
Phase 1 N=12 Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment — 0; 0; 0; 0 participants
Phase 1 N=48 Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
Hantavirus Pulmonary Infection · Immunisation
Primary: Number of Participants Experiencing Clinical Safety Laboratory Adverse Events — 0; 2; 0; 0 participants
Phase 1 N=590 A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Non-Small Cell Lung Cancer ALK-positive · Non-Small Cell Lung Cancer c-Met Dependent · Non-Small Cell Lung Cancer ROS Marker Positive
Primary: Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib — 250; 250; 250; 250 milligram